Search results

Evidence-based recommendations on glofitamab (Columvi) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.

Result type

Technology appraisal guidance

Published

17 October 2023

In development Reference number: GID-TA11488 Expected publication date: TBC

Result type

Technology appraisal guidance

Status

In development

Evidence-based recommendations on idelalisib (Zydelig) for treating chronic lymphocytic leukaemia in adults.

Result type

Technology appraisal guidance

Published

28 October 2015

In development Reference number: GID-TA11768 Expected publication date:  28 October 2026

Result type

Technology appraisal guidance

Status

In development

Evidence-based recommendations on ibrutinib (Imbruvica) for treating chronic lymphocytic leukaemia in adults.

Result type

Technology appraisal guidance

Published

25 January 2017

This guideline covers diagnosing, staging and managing non-Hodgkin lymphoma (NHL) in people aged 16 years and over. It includes radiotherapy, systemic anticancer therapy and stem cell transplantation treatments for follicular, MALT, mantle cell, diffuse large B-cell, Burkitt and peripheral T-cell lymphoma.

Result type

NICE guideline

Published

20 July 2016

Research should be carried out to compare the clinical effectiveness of bendamustine with chlorambucil at the higher dose used in the...

Result type

Research recommendation

Published

9 June 2015

Evidence-based recommendations on glofitamab (Columvi) plus gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma not otherwise specified in adults.

Result type

Technology appraisal guidance

Published

3 December 2025

Evidence-based recommendations on zanubrutinib (Brukinsa) for treating Waldenstrom’s macroglobulinaemia in adults.

Result type

Technology appraisal guidance

Published

19 October 2022

Evidence-based recommendations on loncastuximab tesirine (Zynlonta) for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma in adults after 2 or more systemic treatments.

Result type

Technology appraisal guidance

Published

31 January 2024

View a complete list of all our guidance, NICE advice and quality standards currently in development

Evidence-based recommendations on brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma in adults who have previously had a Bruton’s tyrosine kinase (BTK) inhibitor.

Result type

Technology appraisal guidance

Published

24 February 2021

Discontinued Reference number: GID-TAG278

Result type

Technology appraisal guidance

Status

Discontinued

Discontinued Reference number: GID-TAG321

Result type

Technology appraisal guidance

Status

Discontinued

Evidence-based recommendations on lenalidomide (Revlimid) with rituximab for previously treated follicular lymphoma (grade 1 to 3A) in adults.

Result type

Technology appraisal guidance

Published

7 April 2020